Insulin-like protein points to new diabetes drugs

	Tweet

Japanese investigators have isolated a new compound produced by fat tissue that shares properties with insulin and may lead to the development of new diabetes drugs. They call the protein visfatin.

Visfatin is produced in abdominal visceral fat of both humans and mice. The blood level of the protein “increases during the development of obesity,” the team reports in the journal Science, published online Thursday at the ScienceExpress Web site.

"Surprisingly,” Dr. Iichiro Shimomura, from Osaka University and colleagues write, “visfatin binds to and activates the insulin receptor.”

There are, however, “important differences” between visfatin and insulin, the team notes. For example, visfatin levels do not change markedly with fasting or feeding, as is the case with insulin.

It’s known that obesity, and specifically the accumulation of fat in the abdomen around the visceral organs, is linked to the development of insulin resistance that can lead to overt diabetes. Shimomura explained how visfatin may play into this scenario.

Chronically high levels of visfatin resulting from visceral fat obesity, he said, “may underlie insulin resistance by continuously stimulating insulin receptors.”

Alternatively, “as visfatin activates insulin receptor in a different manner from insulin, visfatin may be useful to treat insulin resistance,” the researcher commented.

Indeed, the researchers found that visfatin displays beneficial insulin-like effects in mice. High doses of synthetic visfatin lowered blood glucose levels in insulin-resistant or insulin-deficient animals.

But as the two authors of a related editorial point out, much remains to be discovered about how visfatin, insulin and glucose are related.

SOURCE: Science, online December 16, 2004.

RELATED STORIES:
Yo-yo weight loss may impair immunity   New drug approved for childhood leukemia   US FDA says generic Wellbutrin OK despite reports   Shut down Internet drug retailing, Boudria says   Rare, drug-resistant HIV strain diagnosed in New York   New leukemia drugs work better, studies show   FDA Warns of Changes in Infant Acetaminophen Dosage   FDA Approves Generic Versions of HIV Drug   Reformulated Imatinib Eliminates Morphine Tolerance in Lab Studies   Roche to supply Tamiflu raw ingredient to Vietnam   Drug resistant H1N1 no major change in virus: WHO   Injectable Osteoporosis Drug Shows Promise

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]